Clinical Trials Browser

Phase 3 × Triple Negative Breast Neoplasms × pembrolizumab × Clear all

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06393374 2026-03-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3 Recruiting

1,530 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

2,454 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 2 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

TroFuse-011

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

ADAPT-TN-III

ADAPT-TN-IV

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

OPT-PEMBRO

KEYNOTE-355

KEYNOTE-119